RMC-035 (G002)
Prevention of Acute Kidney Injury (AKI) after major cardiovascular surgery
Phase 2Under Strategic Review
Key Facts
Indication
Prevention of Acute Kidney Injury (AKI) after major cardiovascular surgery
Phase
Phase 2
Status
Under Strategic Review
Company
About Guard Therapeutics
Guard Therapeutics is a clinical-stage biotech leveraging the protective protein alpha-1-microglobulin (A1M) to develop treatments for acute and chronic kidney injuries. The company's lead candidate, RMC-035, has progressed through Phase 2 studies for acute kidney injury (AKI) following major cardiovascular surgery, though recent strategic reviews suggest a potential pivot. Guard faces the critical challenges of advancing its platform with limited resources while navigating the high-risk, high-reward landscape of nephrology therapeutics.
View full company profile